---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-116736"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-10-19T12:08:31+00:00"
generated_at: "2026-10-19T12:10:04.940101+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ArriVent firmonertinib FURTHER Phase 1b data published in Cancer Cell: ORR 43-68% in EGFR PACC NSCLC

## Summary
- Confirmed ORR 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months by BICR in front-line EGFR PACC-mutant NSCLC.
- Intracranial ORR of 47% (8/17), including 41% complete responses, among 17 patients with baseline brain metastases.
- 80% of evaluable patients achieved complete ctDNA molecular response by cycle 3; those patients showed ORR 70% vs 20% and PFS 15.1 vs 3.0 months.
- EGFR PACC mutations are ~12% of EGFR-mutant tumors with no established targeted standard of care; firmonertinib showed enhanced in vitro potency vs osimertinib.
- Global Phase 3 ALPACCA trial (FURMO-006; NCT07185997) is enrolling, testing firmonertinib vs investigator's choice of osimertinib or afatinib in first-line disease.

## SEC filing metadata
- accession: 0001104659-26-116736
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-10-19T12:08:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-116736
- JSON: https://secwatch.observer/filing/0001104659-26-116736.json
- Plain text: https://secwatch.observer/filing/0001104659-26-116736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.